Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


Obinutuzumab-based immunochemotherapy and maintenance therapy resulted in longer progression-free survival than rituximab-based therapy. High-grade adverse events were more common with obinutuzumab-based chemotherapy. (Funded by F. Hoffmann-La Roche; GALLIUM ClinicalTrials.gov number, NCT01332968 .) …

  • 123456 Profile photo of Madelyn

    In the Gallium trial looking at the role of Obinutuzumab vs rituximab in the first line treatment of FL, there was a 6% PFS benefit but no improvement in CR rates.